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Electrochemical methodsAbstract The development of the pharmaceuticals brought a revolution in human health. These
pharmaceuticals would serve their intent only if they are free from impurities and are administered
in an appropriate amount. To make drugs serve their purpose various chemical and instrumental
methods were developed at regular intervals which are involved in the estimation of drugs. These
pharmaceuticals may develop impurities at various stages of their development, transportation
and storage which makes the pharmaceutical risky to be administered thus they must be detected
and quantitated. For this analytical instrumentation and methods play an important role. This
review highlights the role of the analytical instrumentation and the analytical methods in assessing
the quality of the drugs. The review highlights a variety of analytical techniques such as titrimetric,
chromatographic, spectroscopic, electrophoretic, and electrochemical and their corresponding
methods that have been applied in the analysis of pharmaceuticals.
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Guided by pharmacology and clinical sciences, and driven by
chemistry, pharmaceutical research in the past has played a
crucial role in the progress of development of pharmaceuticals.
The contribution of chemistry, pharmacology, microbiology
and biochemistry has set a standard in the drug discovery
where new drugs are no longer generated only by the imagina-
tion of chemists but these new drugs are the outcome of ex-
change of ideas between biologists and chemists.
The process of drug development starts with the innovation
of a drug molecule that has showed therapeutic value to battle,
control, check or cure diseases. The synthesis and characteriza-
tion of such molecules which are also called active pharmaceu-
tical ingredients (APIs) and their analysis to create preliminary
safety and therapeutic efﬁcacy data are prerequisites to identi-
ﬁcation of drug candidates for further detailed investigations
(Valagaleti et al., 2003).
The investigations on the pre drug discovery are based on
knowing the basic cause of the disease to be treated, the infor-
mation on how the genes are altered that cause the disease, the
interaction of proteins and the affected cells and changes
brought by these affected cells and how they affect these cells.
Based on these facts a compound is developed which interacts
with the affected cells and ﬁnally could become the drug mol-Table 1 Summary of phasewise clinical trial and motive of investig
Phase of clinical trail Number and type of subjects
Phase 1 50–200 healthy subjects (usually) or
patients who are not expected to beneﬁt
from the IMP
Phase 2 100–400 patients with the target disease
Phase 3 1000–5000 patients with the target disease
Phase 4 Many thousands or millions of patients
with the target disease
Source: guidelines in clinical trials: 2007 edition. The Association of the
* IMP: investigational medicinal product i.e. the newly developed drug.ecule or active pharmaceutical ingredient (A.P.I) Drug discov-
ery and Development, understanding the R&D process (http://
www.phrma.org/sites/default/ﬁles/159/
rd_brochure_022307.pdf).
The ‘‘compound’’ which is set to become the drug molecule
undergoes safety tests and a series of experiments to prove that
it is absorbed in the blood stream, distributed to proper site of
action in the body, metabolized sufﬁciently and demonstrates
its non-toxicity thus, can be considered safe and successful.
Once the compound is ﬁnalized the preclinical research i.e.
in vitro studies followed by the animal testing to check kinet-
ics, toxicity and carcinogenicity tests are performed. After
passing the pre-clinical tests the regulatory authorities grant
permission for the clinical trials. The clinical trials check
whether the drug is working in the proposed mechanism or
not, its optimum dose and schedule while the last two stages
generate statistically important data about efﬁcacy, safety
and overall beneﬁt–risk association of the drug. In this phase
the potential interaction of the drug with other medicines is
determined and monitors drug’s long term effectiveness. After
a successful completion of the clinical trials, the drugs are
launched in the market for patients. The summary of various
stages of clinical trials are listed in Table 1.
Development of single-enantiomer drugs was also made
possible by asymmetric synthesis and chiral separationation.
Investigation
Is the IMP safe in humans?
What does the body do to the IMP? (pharmacokinetics)
What does the IMP do to the body? (pharmacodynamics)
Will the IMP work in patients?
Is the IMP* safe in patients?
Does the IMP seem to work in patients?
Is the IMP really safe in patients?
Does the IMP really work in patients
Just how safe is the new medicine? (pharmacovigilance)
How does the new medicine compare with similar medicines?
British Pharmaceutical Industry, 12 Whitehall London.
Table 2 Proportion of various analytical methods prescribed
for the assay of bulk drug materials in Ph. Eur. 4 and USP
XXVII.
Method Ph. Eur.
4 (%)
USP
27 (%)
HPLC 15.5 44
GC 2 2.5
Titration 69.5 40.5
Acid–base 57.5 29.5
Aqueous mixtures 21 5.5
Indicator 6.5 4.5
Potentiometric 14.5 1
Non-aqueous 36.5 24
Indicator 9.5 14
Potentiometric 27 10
Redox (Iodometry, Nitritometry, etc.) 6.5 5.5
Other (complexometry, argentometry,
etc.)
5.5 5.5
UV–vis spectrophotometry 9.5 8.5
Microbiological assay (antibiotics) 3 2.5
Other (IR, NMR, polarimetry,
ﬂuorimetry, atomic absorption
spectroscopy, polarography, gravimetry
etc.)
0.5 2
Source: S. Gorog/Journal of Pharmaceutical and Biomedical
Analysis 36 (2005) 931–937.
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(FDA’s, 1992; Health Canada, 2000; European Medicines
Agency, 1996) have been published which encouraged the
development of single enantiomer drugs for pharmaceutical
manufacturers. The quality of chiral drugs was stipulated by
the guideline of the International Conference on Harmoniza-
tion of Technical Requirements for the Registration of Phar-
maceuticals for Human Use (ICH) (ICH Topic Q 6 A,
1999). The guideline recommends applicants to consider other
enantiomer as an impurity and to set the identity tests capable
of distinguishing both enantiomers and the racemic mixture. It
is required to provide tools for efﬁcient quality systems ensur-
ing safe and proper manufacturing processes (ICH, 2009).
However, insufﬁcient in-process control may result in the
products suffering from surface irregularities (Akseli et al.,
2008; Varghese and Cetinkaya, 2007). In addition, the ﬁnished
products may contain unidentiﬁed foreign matter particles.
The foreign matter has to be identiﬁed and its source should
be deﬁned in order to prevent further contamination. Hence
it is required to provide an efﬁcient detection and identiﬁcation
procedure of foreign matter from the dosage forms by utiliza-
tion of analytical techniques (Pajander et al., 2013).
The drugs which are marketed may have different dosage
forms. Formulation can be categorized according to the route
of administration (Pifferi et al., 1999). Pharmaceutical develop-
ment information provides the scientiﬁc rationale for formula-
tion development and justiﬁcation for a suitable dosage form.
Regulatory guidance provides only limited details of the
requirements for the data sets associated with the pharmaceuti-
cal development (U.S Department of Health, 2003) but more
detailed information are available for the toxicological assess-
ment of excipients (U.S Department of Health, 2002). Excipi-
ents are the major fraction of the solid dosage forms which
serve as diluents to allow the formulation of appropriately sized
tablets and coatings to protect the tablet from undesirable orga-
noleptic qualities of the drug substance. Solid state reactions in
the dosage form can occur when the drug substance is reactive
and may be accelerated by physical and chemical interaction
with excipients. In some cases excipients do not interact chem-
ically but promotes the degradation of drug substance (Bryn
et al., 2001). For example, primary and secondary amines can
react with lactose, glucose and maltose to form glycosylamines
(Serajuddin et al., 1999; Wirth et al., 1998).
In the ﬁeld of pharmaceutical research, the analytical inves-
tigation of bulk drug materials, intermediates, drug products,
drug formulations, impurities and degradation products, and
biological samples containing the drugs and their metabolites
is very important. From the commencement of ofﬁcial phar-
maceutical analysis, analytical assay methods were included
in the compendial monographs with the aim to characterize
the quality of bulk drug materials by setting limits of their ac-
tive ingredient content. In recent years, the assay methods in
the monographs include titrimetry, spectrometry, chromatog-
raphy, and capillary electrophoresis; also the electro analytical
methods can be seen in the literature. The present state-of-the-
art is replicated through the data in Table 2 based on the edi-
tion of European (The European Pharmacopoeia and Council
of Europe, 2002) and US (United States Pharmacopoeia, 2004)
pharmacopoeias.
From the stages of drug development to marketing and
post marketing, analytical techniques play a great role, be it
understanding the physical and chemical stability of the drug,impact on the selection and design of the dosage form, assess-
ing the stability of the drug molecules, quantitation of the
impurities and identiﬁcation of those impurities which are
above the established threshold essential to evaluate the toxic-
ity proﬁles of these impurities to distinguish these from that of
the API, when applicable and assessing the content of drug in
the marketed products. The analysis of drug and its metabolite
which may be either quantitative or qualitative is extensively
applied in the pharmacokinetic studies.
This review highlights the role of various analytical tech-
niques and their corresponding analytical methods in the anal-
ysis of pharmaceuticals.
2. Analytical techniques
2.1. Titrimetric techniques
Origin of the titrimetric method of analysis goes back to some-
where in the middle of the 18th century. It was the year 1835
when Gay–Lussac invented the volumetric method which sub-
sequently leads to the origin of term titration. Although the as-
say method is very old yet there are signs of some
modernization, i.e., spreading of non-aqueous titration meth-
od, expanding the ﬁeld of application of titrimetric methods
to (very) weak acids and bases as well as potentiometric end
point detection improving the precision of the methods. With
the development of functional group analysis procedures titri-
metric methods have been shown to be beneﬁcial in kinetic mea-
surements which are in turn applied to establish reaction rates.
There are many advantages associated with these methods
which include saving time and labor, high precision and the fact
that there is no need of using reference standards. In the past
titrimetric methods have been used for the determination of
captopril (Rahman et al., 2005a), albendozole (Basavaiah and
Table 3 Chromatographic adsorbents: (approximate order is
shown in the table, since it depends upon the substance being
adsorbed, and the solvent used for elution).
Most strong adsorbent Alumina Al2O3
Charcaol C
Florisil MgO/SiO2 (anhydrous)
Least strong adsorbent Silica gel SiO2
Source: http://www.chem.wisc.edu/courses/342/Fall2004/TLC.pdf.
S1412 M.R. Siddiqui et al.Prameela, 2003) and gabapentin (Sameer and Abdulrahman
Basavaiah, 2011) in commercial dosage forms. Sparﬂoxacin
(Marona and Schapoval, 2001) was determined by the non-
aqueous titration method. In addition to its application in drug
estimation titrimetry has been used in the past for the estimation
of degradation products of the pharmaceuticals (Matei et al.,
2008).
2.2. Chromatographic techniques
2.2.1. Thin layer chromatography
Although an old technique yet it ﬁnds a lot of application in
the ﬁeld of pharmaceutical analysis. In thin layer chromatogra-
phy, a solid phase, the adsorbent, is coated onto a solid sup-
port as a thin layer usually on a glass, plastic, or aluminum
support. Several factors determine the efﬁciency of this type
of chromatographic separation. First the adsorbent should
show extreme selectivity toward the substances being separated
so as to the dissimilarities in the rate of elution be large. For
the separation of any given mixture, some adsorbents may
be too strongly adsorbing or too weakly adsorbing. Table 3
lists a number of adsorbents in the order of adsorptive power.
Thin layer chromatography is a popular technique for the
analysis of a wide variety of organic and inorganic materials,
because of its distinctive advantages such as minimal sample
clean-up, wide choice of mobile phases, ﬂexibility in sample
distinction, high sample loading capacity and low cost. TLC
is a powerful tool for screening unknown materials in bulk
drugs (Szepesi and Nyiredy, 1996). It provides a relatively high
degree of assertion that all probable components of the drug
are separated. The high speciﬁcity of TLC has been exploited
to quantitative analytical purpose using spot elution followed
by spectrophotometric measurement. TLC has been utilized
for the determination of some steroids (Cimpoiu et al.,
2006), pioglitazone (Gumieniczek et al., 2004), celecoxib (Be-
bawy et al., 2002) and noscapine (Ashour et al., 2009). TLC
plays a crucial role in the early stage of drug development
when information about the impurities and degradation prod-
ucts in drug substance and drug product is inadequate. Vari-
ous impurities of pharmaceuticals have been identiﬁed and
determined using TLC (White et al., 1992; Agbaba et al.,
1996).
2.2.2. High performance thin layer chromatography
With the advancement of the technique, high performance thin
layer chromatography (HPTLC) emerged as an important
instrument in drug analysis. HPTLC is a fast separation tech-
nique and ﬂexible enough to analyze a wide variety of samples.
This technique is advantageous in many means as it is simple
to handle and requires a short analysis time to analyze thecomplex or the crude sample cleanup. HPTLC evaluates the
entire chromatogram with a variety of parameters without
time limits. Moreover, there is simultaneous but independent
development of multiple samples and standards on each plate,
leading to an increased reliability of results. HPTLC has been
used to quantitate drugs as ethinyl estradiol and cyproterone
(Pavic et al., 2003), alfuzosin (Fayed et al., 2006) and tramadol
and pentazocine (Ebrahim et al., 2011).
2.2.3. High-performance liquid chromatography (HPLC)
HPLC is an advanced form of liquid chromatography used in
separating the complex mixture of molecules encountered in
chemical and biological systems, in order to recognize better
the role of individual molecules. It was in the year 1980, HPLC
methods appeared for the ﬁrst time for the assay of bulk drug
materials (United States Pharmacopoeia, 1980). As seen in Ta-
ble 2, this has become the principal method in USP XXVII
(United States Pharmacopoeia, 2004) and to a lesser extent
but one of the most widely used methods also in Ph. Eur. 4
(The European Pharmacopoeia and Council of Europe, 2002).
The speciﬁcity of the HPLC method is excellent and simul-
taneously sufﬁcient precision is also attainable. However, it
has to be stated that the astonishing speciﬁcity, precision and
accuracy are attainable only if wide-ranging system suitability
tests are carried out before the HPLC analysis. For the reason
the expense to be paid for high speciﬁcity, precision and accu-
racy is also high.
During the survey of the literature it was observed that
among the chromatographic techniques HPLC has been the
most widely used system. In liquid chromatography the choice
of detection approach is critical to guarantee that all the com-
ponents are detected. One of the widely used detectors in
HPLC is UV detector which is capable of monitoring several
wavelengths concurrently; this is possible only by applying a
multiple wavelength scanning program. If present in adequate
quantity, UV detector assures all the UV-absorbing compo-
nents are detected.
A photodiode array (PDA) is a lined array of discrete pho-
todiodes on an integrated circuit (IC) chip for spectroscopy. It
is placed at the image plane of a spectrometer to allow a range
of wavelengths to be sensed concurrently. When a variable
wavelength detector (VWD) is used a sample must be injected
numerous times, with changing wavelength, to be sure that all
the peaks are detected. In the case of PDA, when it is used a
wavelength range can be programed and all the compounds
that absorb within this range can be identiﬁed in a single anal-
ysis. PDA detector can also analyze peak purity by matching
spectra within a peak. PDA detector ﬁnds its application in
the method development of Iloperidone in pharmaceuticals
(Devi Manjula and Ravi, 2012).
The refractive index detector is the detector of choice when
one needs to detect analytes with restricted or no UV absorp-
tion such as alcohols, sugars, carbohydrates, fatty acids, and
polymers. Decent trace detection performance is secured
through a low noise. This detector is having the lowest sensitiv-
ity among all detectors but suitable at high analyte concentra-
tions. Lakshmi and Rajesh utilized the refractive index
detector to analyze the content of volgibose in pharmaceutical
formulations (Lakshmi and Rajesh, 2010). The electrochemical
detector responds to the substances that are either oxidizable
or reducible and the electrical output results from an electron
ﬂow triggered by the chemical reaction that takes place at the
Analytical techniques in pharmaceutical analysis: A review S1413surface of the electrode. This detector was applied recently to
analyze the content of glutathione in human prostate cancer
cells and lung adenocarcinoma cells (Spadaro et al., 2011).
One of the most sensitive detectors among the LC detectors
is ﬂuorescence detector. Typically its sensitivity is 10–1000
times higher than that of the UV detector for strong UV
absorbing materials used as an advantage in the measurement
of speciﬁc ﬂuorescent species in samples. One of the most
important applications of ﬂuorescence is the estimation of
pharmaceuticals (Ulu and Tuncel, 2012). The application of
various types of detector in HPLC is compared in Fig. 1.
Over a certain period of time most workers used the re-
versed-phase mode with UV absorbance detection whenever
appropriate, because this provided the best available reliabil-
ity, analysis time, repeatability and sensitivity. Several drugs
have been assayed in pharmaceutical formulations (Siddiqui
et al., 2010; Tang et al., 2012; Devika et al., 2012; Ahmed
et al., 2012) and in biological ﬂuids (Tariq et al., 2010; Sama-
nidou et al., 2012; Malenovic´ et al., 2012; Giorgi et al., 2012)
using HPLC. Thus, HPLC provides a major service in answer-
ing many questions posed by the pharmaceutical industry.
However, the limitations of HPLC include price of columns,
solvents and a lack of long term reproducibility due to the pro-
prietary nature of column packing. Liquid chromatography
combined with mass spectrometry (LC–MS) is considered as
one of the most important techniques of the last decade of
20th century (Niessen, 1999). It became the method-of-choice
for analytical support in many stages of quality control and
assurance within the pharmaceutical industry (Ermer, 1998;
Nicolas and Scholz, 1998). Recently HPLC-MS has been used
for assay of drugs (Hilhorst et al., 2011; D’Avolio et al., 2010;
Berset et al., 2010; Ding et al., 2006; Wren and Tchelitcheff,
2006; Zhou et al., 2011; Breaud et al., 2009). In addition toFigure 1 Usage of different detectors for HPLC analysis of drugs, S
Rao, V. Nagaraju. J. Pharm. Biomed. Anal. 2003, 33, 335–377.its application in analyzing the drugs HPLC alone and with
hyphenated technique have been applied to analyze the impu-
rities of the pharmaceuticals (Chitturi et al., 2011; Madireddy
et al., 2011; Navaneeswari and Reddy, 2011; Thomas et al.,
2012; Verbeken et al., 2011) and degradation products (Sabry
et al., 2012; Hanysova et al., 2005; Bouchonnet et al., 2012).
2.2.4. Gas chromatography
Moving ahead with another chromatographic technique, gas
chromatography is a powerful separation technique for detec-
tion of volatile organic compounds. Combining separation
and on-line detection allows accurate quantitative determina-
tion of complex mixtures, including traces of compounds
down to parts per trillions in some speciﬁc cases. Gas liquid
chromatography commands a substantial role in the analysis
of pharmaceutical product (Watson, 1999). The creation of
high-molecular mass products such as polypeptides, or ther-
mally unstable antibiotics conﬁnes the scope of this technique.
Its main constraint rests in the comparative non-volatility of
the drug substances therefore, derivatization is virtually com-
pulsory. Recently, gas chromatography has been used for as-
say of drugs such as isotretinion (Lima et al., 2005), cocaine
(Zuo et al., 2004) and employed in the determination of resid-
ual solvents in betamethasone valerate (Somuramasami et al.,
2011). Gas chromatography is also an important tool for
analysis of impurities of pharmaceuticals. In recent years
GC has been applied to estimate the process related impuri-
ties of the pharmaceuticals (Frost et al., 2003; Hiriyanna
and Basavaiah, 2008), residual solvents listed as impurity by
the International Conference of Harmonization are analyzed
by the GC using a variety of detectors (Reddy and Reddy,
2009; Hashimoto et al., 2001; Saraji et al., 2012; Deconinck
et al., 2012).cale 0–100 represents use of the detector percentage. Source: R.N.
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2.3.1. Spectrophotometry
Another important group of methods which ﬁnd an important
place in pharmacopoeias are spectrophotometric methods
based on natural UV absorption and chemical reactions (Gor-
og, 1995). Spectrophotometry is the quantitative measurement
of the reﬂection or transmission properties of a material as a
function of wavelength.
The advantages of these methods are low time and labor
consumption. The precision of these methods is also excel-
lent. The use of UV–Vis spectrophotometry especially applied
in the analysis of pharmaceutical dosage form has increased
rapidly over the last few years (Tella et al., 2010; Venugopal
and Sahi, 2005; Sharma et al., 2008; Ieggli et al., 2005). The
colorimetric methods are usually based on the following
aspects:
 Complex-formation reaction.
 Oxidation-reduction process.
 A catalytic effect.
It is important to mention that colorimetric methods are
regularly used for the assay of bulk materials. For example,
the blue tetrazolium assay is used for the determination of cor-
ticosteroid drug formulations (Gorog and Szasz, 1978; Gorog,
1983). The colorimetric method is also exploited for the deter-Table 4 Quantitative analysis of drugs in pharmaceutical formulat
Reagent used Name of drug
m-Cresol Acetaminophen
p-Chloranilic acid Quetiapine fumarat
Milrinone
2,3-Dichloro 5,6-dicyano1,4-benzoquinone Duloxetine
Amlodipine besylat
Chloranil Dutasteride
Lisinopril
7,7,7,8-Tetracyanoquinodimethane Lisinopril
Alendronate sodium
Iodine Flunarizine dihydro
Aripiprazole
Potassium iodide and potassium iodate Irbesartan
Ninhydrin Pregabalin
Ascorbic acid Lisinopril
Folin ciocalteu phenol Oxcarbazepine
Ampicillin, amoxyc
Tris buﬀer Diclofenac sodium
Sodium metavanadate Diltiazem HCl
Bromothymol blue Rasagiline mesylate
Bromophenol blue Rasagiline mesylate
Bromocresol green Rasagiline mesylate
Potassium permanganate in alkaline medium Isatin
Brucine-sulfanilic acid in H2SO4 medium Nicorandil
3-Methyl-2-benzothiazoline Nicorandil
Cu (II) & eosin Carbinoxamine
Potassium ferricyanide and ammonium ferric sulfate Pantoprazole sodiu
Chloramin T Zidovudine
Verapamil HClmination of cardiac glycosides and is presented in European
Pharmacopoeia. Several approaches using spectrophotometry
for determination of active pharmaceutical ingredients in bulk
drug and formulations have been reported and details of these
methods are recorded in Table 4.
Derivative spectroscopy uses ﬁrst or upper derivatives of
absorbance with respect to wavelength for qualitative investi-
gation and estimation. The concept of derivatizing spectral
data was ﬁrst offered in the 1950s, when it was shown to have
many advantages. However, the technique received little con-
sideration primarily due to the complexity of generating deriv-
ative spectra using early UV–Visible spectrophotometers. The
introduction of microcomputers in the late 1970s made it gen-
erally convincing to use mathematical methods to generate
derivative spectra quickly, easily and reproducibly. This signif-
icantly increased the use of the derivative technique. The deriv-
ative method has found its applications not only in UV-
spectrophotometry but also in infrared (McWilliams, 1969),
atomic absorption, ﬂuorescence spectrometry (Snelleman
et al., 1970; Konstantianos et al., 1994), and ﬂuorimetry
(O’Haver, 1976; John and Soutar, 1976). The use of derivative
spectrometry is not restricted to special cases, but may be of
advantage whenever quantitative study of normal spectra is
problematic. Disadvantage is also associated with derivative
methods; the differential degrades the signal-to-noise ratio,
so that some form of smoothing is required in conjunction
with differentiation (O’Haver and Begley, 1961).ions by UV–visible spectrophotometric procedures.
kmax Reference
640 Qureshi et al. (1992)
e 520 Vinay and Revenasiddappa (2012)
519 Siddiqui et al. (2009)
477 Toker and O¨nal (2012)
e 580 Rahman and Hoda (2003)
525 Kumar et al. (2012)
520 Rahman et al. (2007)
743 Rahman et al. (2005b)
840 Raza and Haq (2011)
chloride 380 El Walily et al. (1995)
400 Helmy et al. (2012)
352 Rahman et al. (2006a)
402.6 Bali and Gaur (2011)
530 Rahman et al. (2005c)
760 Gandhimathi and Ravi (2008)
illin, and carbenicillin 750, 770, 750 Ahmad et al. (2004)
284, 305 Kramancheva et al. (1997)
750 Rahman and Azmi (2000)
414 Chennaiah et al. (2011)
414 Chennaiah et al. (2011)
414 Chennaiah et al. (2011)
60 AlOthman et al. (2013)
410 Rahman et al. (2004)
560 Rahman et al. (2004)
538 Ramadan and Mandil (2006)
m 725 Rahman et al. (2006b)
520 Basavaiah and Anil Kumar, 2007
425 Rahman and Hoda (2002)
Analytical techniques in pharmaceutical analysis: A review S14152.3.2. Near infrared spectroscopy (NIRS)
Near infrared spectroscopy (NIRS) is a rapid and non-destruc-
tive procedure that provides multi component analysis of al-
most any matrix. In recent years, NIR spectroscopy has
gained a wide appreciation within the pharmaceutical industry
for raw material testing, product quality control and process
monitoring. The growing pharmaceutical interest in NIR spec-
troscopy is probably a direct consequence of its major advanta-
ges over other analytical techniques, namely, an easy sample
preparation without any pretreatments, the probability of sep-
arating the sample measurement position by use of ﬁber optic
probes, and the expectation of chemical and physical sample
parameters from one single spectrum. Themajor pharmacopoe-
ias have generally adopted NIR techniques. The European
Pharmacopoeia in chapter 2.2.40 (The European Pharmaco-
poeia and Council of Europe, 2002) and United States pharma-
copoeias (chapter 1119 United States Pharmacopoeia USP 26
NF 21, 2003) address the suitability of NIR instrumentation
for application in pharmaceutical testing. NIR spectroscopy
in combination with multivariate data analysis opens many
interesting perceptions in pharmaceutical analysis, both quali-
tatively and quantitatively. A number of publications describing
quantitative NIR measurements of active ingredient in intact
tablets have been reported (Moffat et al., 2000; Alvarenga et al.,
2008; Thosar et al., 2001; Ramirez et al., 2001; Blanco et al.,
1996, 1999, 2000; Li et al., 2003; Molt et al., 1996; Buchanan
et al., 1996; Merckle and Kovar, 1998; Eustaquino et al.,
1998; Traford et al., 1999; Corti et al., 1999; Chen et al.,
2001). In addition to the research articles many review articles
have been published citing the application of the NIRS in phar-
maceutical analysis (Luypaert et al., 2007; Blanco et al., 1998).
2.3.3. Nuclear magnetic resonance spectroscopy (NMR)
Since the ﬁrst report appeared in 1996 (Shuker et al., 1996)
describing the use of NMR spectroscopy to screen for the drug
molecules, the ﬁeld of NMR based screening has proceeded
promptly. Over the last few years, a variety of state-of-the-
art approaches have been presented and found a widespread
application in both pharmaceutical and academic research.
Recently NMR ﬁnds its application in quantitative analysis
in order to determine the impurity of the drug (Mistry et al.,
1999), characterization of the composition of the drug prod-Table 5 Determination of drug by various electrochemical techniqu
Technique Drugs determined Remark
Voltammetry b-blocker drugs Naﬁon-coated glassy ca
Rosiglitazone Square wave adsorptiv
Leucovorin Silver solid amalgam e
Secnidazole Cathodic adsorptive st
Acetaminophen and tramadol At glassy carbon paste
Dopamine Diﬀerential pulse stripp
Atenolol Using nanogold modiﬁ
Polarography Nifedipine
Anti cancer drug, Vitamin K3
Ciclopirox olamine
Amperometry Diclofenac
Verapamil
Potentiometry N-acetyl-L-cysteine
Pentoxifyllineucts and in quantitation of drugs in pharmaceutical formula-
tions and biological ﬂuids (Salem et al., 2006; Reinscheid,
2006), Many reviews on the application of NMR in pharma-
ceuticals have been published (Holzgrabe et al., 2005; Malet-
Martino and Holzgrabe, 2011).
2.3.4. Fluorimetry and phosphorimetry
The pharmaceutical industries continuously look for the sensi-
tive analytical techniques using the micro samples. Fluores-
cence spectrometry is one of the techniques that serve the
purpose of high sensitivity without the loss of speciﬁcity or
precision. A gradual increase in the number of articles on the
application of ﬂuorimetry (Rahman et al., 2012, 2009) and
phosphorimetry (De Souza et al., 2013; Chuan et al., 2000)
in quantitative analysis of various drugs in dosage forms and
biological ﬂuids has been noticed in the recent past.
2.4. Electrochemical methods
The application of electrochemical techniques in the analysis
of drugs and pharmaceuticals has increased greatly over the
last few years. The renewed interest in electrochemical tech-
niques can be attributed in part to more sophisticated instru-
mentation and to increase the understanding of the
technique themselves. Here the application of various electro-
chemical modes in the analysis of drugs and pharmaceuticals is
presented in Table 5.
Moreover, a large number of electroanalytical methods are
available for quantiﬁcation of pharmaceuticals. An amberlite
XAD-2 and titanium dioxide nanoparticles modiﬁed glassy car-
bon paste was developed for the determination of imipramine,
trimipramine and desipramine. The electrochemical behavior
of these drugs was investigated using cyclic voltammetry, chro-
nocoulometry, electrochemical impedence spectroscopy and
adsorptive stripping differential pulse voltammetry (Sanghavi
and Srivastava, 2013).The capsaicin modiﬁed carbon nanotube
modiﬁed basal-plane pyrolitic graphite electrode or p-chloranil
modiﬁed carbon paste electrodes have been developed for the
determination of benzocaine and lidocaine. The electrochemi-
cally initiated formation of capsaicin-benzocaine adduct causes
a linear decrease in the voltammetric signal corresponding to
capsaicin which correlates to the added concentration ofes.
Reference
rbon electrode Nigovic´ et al. (2011)
e stripping voltammetry Al-Ghamdi and Hefnawy (2012)
lectrode Sˇelesˇovska´ et al. (2012)
ripping voltammetry El-Sayed et al. (2010)
electrode Sanghavi and Srivastava (2011a)
ing voltammetry Abdoljavadi and Masrournia (2011)
ed indium tin oxide electrode Goyal et al. (2005)
Jeyaseelan et al. (2011)
TasAˆ et al. (2011)
Ibrahim and El-Enany (2003)
Gimenes et al. (2011)
Ortuno et al. (2005)
Prkic´ et al. (2011)
Alarfaj and El-Tohamy (2011)
S1416 M.R. Siddiqui et al.benzocaine (Kachoosangi et al., 2008). A copper (II) complex
and silver nanoparticles modiﬁed glassy carbon paste electrode
was constructed and used for the determination of dopamine,
levodopa, epinephrine and norepinephrine. The electrochemical
behavior of these drugs was studied using cyclic voltammetry,
electrochemical impedance spectroscopy, chronocoulometry
and adsorptive stripping square-wave voltammetry techniques
(Sanghavi et al., 2013). The electrochemical behavior of clio-
quinol, a molecule with a large spectrum of clinical applications,
was studied by cyclic, differential pulse and square-wave vol-
tammetry over a wide pH range using a glassy carbon electrode
(Ghalkhani et al., 2011). Adsorptive stripping differential pulse
voltammetric method has been developed for the determination
of venlafaxine and desvenlafaxine using Naﬁon-carbon nano-
tube composite glassy carbon electrode (Sanghavi and Srivast-
ava, 2011b). A carbon nanotube paste electrode modiﬁed
in situ with Triton X 100 was developed for the individual and
simultaneous determination of acetaminophen, aspirin and caf-
feine (Sanghavi and Srivastava, 2010). An electrochemical
method based on potentiometric stripping analysis employing
cryptand and carbon nanotube modiﬁed paste electrode has
been proposed for the subnanomolar determination of bismuth
(Gadhari et al., 2010). A novelmethod, capillary electrophoresis
with amperometric detection, has been established for rapid and
effective measurement of levodopa and bensevazide and its
impurity (R,S)-2-amino-3-hydroxy propanohydrazide in co-
beneldopa pharmaceutical formulations (Wang et al., 2005).
Potentiometric stripping analysis of antimony based on carbon
paste electrode modiﬁed with hexathia crown ether and rice
husk has also been reported (Gadhari et al., 2011).
2.5. Kinetic method of analysis
Kinetic method of analysis has been developing since 1950s
and yet in modern days it is taking a major resurgence in activ-
ity. The repetitive interest in the kinetic methods can be cred-
ited to the advancements made in principles, in automated
instrumentation, in understanding the chemical and instru-
mentation, in data analysis methods and in the analytical
application.
From the literature it is evident that the kinetic approach to
analytical chemistry is rather general with several advantages
over traditional equilibrium approach (Pardue, 1989; Mottola,
1988; Perez-Bendito and Silva, 1988). Essentially, kinetic meth-
ods trust the measurements of concentration changes (detected
via signal changes) in a reactant (which may be the analyte it-
self) with time after the sample and reagents have been mixed
manually or mechanically.
Going through the literature it can be evident that ﬁxed-
time and initial rate methods have been used more often for
the determination of drugs in pharmaceutical formulations
(Darwish et al., 2010; Rahman and Kashif, 2010). Automatic
techniques for the kinetic methods are generally based on open
systems, among the popular techniques are the stopped ﬂow
system (Andrade et al., 2010) and the continuous addition of
reagent (CAR) technique (Jimenez-Prieto and Silva, 1998,
1999). Several drugs have been determined by using the
CAR technique with photometric (Marquez et al., 1990) and
ﬂuorimetric detection (Marquez et al., 1989). The usage of cat-
alysts to accelerate analytical reactions is feasible with both
reaction rate and equilibrium estimations. The use of micellar
media in kinetic method is recently encouraged to enhance therate of reaction, through micellar catalysis and may addition-
ally improve the sensitivity and the selectivity which in turn les-
sen the analysis time for the analyte (Monferrer-Pons et al.,
1999; Pe´rez-Bendito et al., 1999; Georgiou et al., 1991).
Multicomponent kinetic estimations, most often referred to
as differential rate methods, are also receiving wide acceptance
in the ﬁeld of pharmaceutical research (Sultan and Walmsley,
1997). Two new approaches i.e. kinetic wavelength pair meth-
od (Pena et al., 1991) and H-point standard addition method
(Givianrad et al., 2011) have been proposed for dealing with
overlapping spectra of components in the binary mixtures.
2.6. Electrophoretic methods
Another important instrument essential for the analysis of
pharmaceuticals is capillary electrophoresis (CE). CE is a rela-
tively new analytical technique based on the separation of
charged analytes through a small capillary under the impact
of an electric ﬁeld. In this technique solutes are perceived as
peaks as they pass through the detector and the area of indi-
vidual peak is proportional to their concentration, which al-
lows quantitative estimations. In addition to pharmaceutical
studies it ﬁnds an application in the analysis of biopolymer
analysis and inorganic ions. CE analysis is generally more
effective, can be performed on a quicker time scale, requires
only a small amount, lesser up to Nano liter injection volumes,
and in most cases, takes place under aqueous conditions. These
four characteristics of CE have proven to be beneﬁcial to many
pharmaceutical applications. Several reports have appeared on
the application of this technique in the routine drug analysis
(Nehme´ et al., 2010; Zhang et al., 2009; Calcara et al., 2005).
Different modes of capillary electrophoresis such as capillary
zone electrophoresis (Hamoudora and Pospisilova, 2006;
Nevado et al., 2006; Hauze et al., 2005; Ne´meth et al., 2011;
Amin et al., 2012), micellar electrokinetic chromatography
(Hamoudova et al., 2006; Al Azzam et al., 2011; Theurillat
et al., 2010), isotachophoresis (Pospisilova et al., 2005; Kuba-
cak et al., 2005), capillary gel electrophoresis (Liu et al., 1995;
Srivatsa et al., 1994), isoelectric focusing (Lasdun et al., 2001;
Liu et al., 1996) and afﬁnity capillary electrophoresis (Li et al.,
2011; Martinez-Pla et al., 2004) have been developed and ap-
plied to pharmaceutical purity testing and in bio analysis of
drugs.
2.7. Flow injection and sequential injection analysis
Laboratory automation was introduced in the second half of
the XX century. Steward in the U.S. as well as Ruzicka and
Hansen in Denmark, created the ﬂow injection analysis (FIA)
technique for the automation of chemical procedure (Stewart
et al., 1976; Ruzicka and Hansen, 1975). The introduction of
this technique approached to transform the conception of auto-
mation in chemical analysis by permitting instrumental mea-
surement to be carried out in the absence of physical and
chemical equilibria (Ruzicka and Hansen, 1988; Valcarcel and
Luque de Castro, 1987; Karlberg and Pacey, 1989). The basis
of Flow injection analysis (FIA) is injection of a liquid sample
into a moving, non-segmented uninterrupted carrier stream of
a suitable liquid. The injected sample forms a zone, which is
then transported toward a detector that uninterruptedly records
the changes in absorbance, electrode potential, or other physical
Figure 2 Stages of ﬂow injection analysis. Source: http://
ww2.chemistry.gatech.edu/class/analyt/ﬁa.pdf.
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through the ﬂow cell. The stages of ﬂow injection analysis have
been shown in Fig. 2.
Following the broad application of computers in routine
laboratory a second generation of ﬂow analysis was offered
by Ruzicka and Marshall (1990), who titled it as sequential
injection analysis (SIA). As with the FIA, this is a non-seg-
mented continuous ﬂow arrangement based on the similar
principle of controlled dispersion and reproducible manipula-
tion of the FIA perception, but whose mode of operation is
based on the theory of programmable ﬂow.
The FIA technique has lent an signiﬁcant contribution to the
advancement of automation in pharmaceutical analysis and its
advantages are well documented in several review articles (Kar-
licek et al., 1994; Calatayud et al., 1990; Calatayud and Garcia
Mateo, 1992a,b; Evagen’ev et al., 2001; Fletcher et al., 2001) as
well as in a specialized monograph (Calatayud, 1996).
The introduction of SIA has awakened the interest of the
scientiﬁc community for automation in the pharmaceutical
area (Christian, 1992). Many articles dedicated to pharmaceu-
tical analysis have been published, including two review arti-
cles (Liu and Fang, 2000; Solich et al., 2004), applying
sequential injection analysis to a wide variety of matrices, such
as solid matrices, pastes (ointments, creams), liquids (emul-
sions, suspensions, solutions) and covering various active
ingredients with different healing activities. By proﬁting from
the advantages in the economy of reagents and the elevated
sampling rates, the majority of the applications are dedicated
to the determination of active ingredients for quality control
in pharmaceutical formulations.
2.8. Hyphenated techniques
The coupling of a separation technique and on-line separation
technique leads to the development of a hyphenated technique.
The last two decades saw a remarkable advancement in the
hyphenated techniques and its application in pharmaceutical
analysis. A variety of hyphenated techniques such as LC-MS
(Qian et al., 2012; Wang et al., 2012; Nandakumar et al.,
2012), GC-MS (De Lima Gomes et al., 2011; Wollein and Sch-ramek, 2012), LC-NMR (Lindon et al., 2000), CE-ICP-MS
(Timerbaev et al., 2012) and CE-MS (Blasco et al., 2009) have
been applied in the analysis of pharmaceuticals. The determi-
nation of drugs in biological materials is an important step
in drug discovery and drug development. The determination
of drugs in biological materials is an important step in drug
discovery and drug development. HPLC together with various
types of detection such as ultraviolet, ﬂuorescence,and mass
spectrometry has become the method of choice for bioanalyt-
ical method development (Nova´kova´ et al., 2008). Recently a
review of HPLC with UV or MS/MS‘ detection is presented
for the analysis of meloxicam in biological samples and phar-
maceutical formulations (Brezovska et al., 2013). Liquid chro-
matography-electrospray ionization–mass spectrometry
method for the qualitative and quantitative determination of
metabolites after oral administration of Rhizome coptidis
and Zuojinwan preparation in rat urine has been developed
(Rui et al., 2012), the same analytical technique was used for
the simultaneous determination of L-ascorbic acid and acetyl
salicylic acid in aspirin C effervescent tablet (Wabaidur
et al., 2013). Urine samples were separated on a C18 column
using a mixture of water (containing 0.1% formic acid) and
acetonitrile (30:70 v/v) as the mobile phase. Recreational drug
abuse is a growing issue and new substances are detected fre-
quently in clinical and forensic samples. Diphenyl-2-pyrroli-
dinemethanol is one of these substances and therefore work
has been done to identify it and its metabolites in rat urine
using gas chromatography–mass spectrometry and liquid chro-
matography–high resolution–mass spectrometry (Meyer et al.,
2013). Experiments were performed to identify the presence of
human pharmaceuticals in the tropical aquatic environment of
Malaysia. Water samples collected at different sites along the
Langat River and efﬂuents from ﬁve sewage treatment plants
were extracted by solid phase extraction and analyzed using li-
quid chromatography coupled with tandem mass spectrometry
(Al-Odaini et al., 2013). This study conﬁrmed the presence of
mefenamic acid, salicylic acid and glibenclamide in all river
water samples. Drug–drug interaction of rabeprazole and clop-
idogrel in healthy Chinese volunteers has been studied. The
plasma concentrations of rabeprazole and clopidogrel were
analyzed by LC-MS/MS at different time intervals after
administration (Wu et al., 2013). A novel LC-MS/MS method
has been developed for the detection of carbapenemase activity
from bacterial isolates (Peaper et al., 2013). A HPLC-MS/MS
method has been reported for the determination of six kinds of
parabens in food (Cao et al., 2013). The method was success-
fully applied to the determination of methyl, ethyl, propyl, bu-
tyl, isopropyl and isobutyl esters of 4-hydroxybenzoic acid. To
assess the pharmacokinetics of selective substrates of human
cytochrome P450s in mini pigs, caffeine, warfarin, omeprazole,
metoprolol and midazolam were administered in combination
either through intravenous route or orally. Plasma samples
obtained upto 24 h after dosing were analyzed by liquid
chromatography–tandem mass spectrometry to estimate
typical pharmacokinetic parameters for each analyte (Mogi
et al., 2012).
3. Conclusion
The main aim of the pharmaceutical drugs is to serve the hu-
man to make them free from potential illness or prevention
S1418 M.R. Siddiqui et al.of the disease. For the medicine to serve its intended purpose
they should be free from impurity or other interference which
might harm humans. This review is aimed at focusing the role
of various analytical instruments in the assay of pharmaceuti-
cals and giving a thorough literature survey of the instrumen-
tation involved in pharmaceutical analysis. The review also
highlights the advancement of the techniques beginning from
the older titrimetric method and reaching the advanced
hyphenated technique stages.Acknowledgements
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